title: Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis.
abstract: OBJECTIVE
  To define the role of intravitreal bevacizumab in individuals with choroidal neovascularization (CNV) resulting from Ocular Histoplasmosis syndrome (OHS).
  
  
  METHODS
  Retrospective chart review of a surgical therapy.
  
  
  METHODS
  We reviewed the course of 28 eyes of 28 patients who underwent intravitreal injection of bevacizumab for treatment of CNV secondary to OHS. Outcome was measured by pretreatment and posttreatment visual acuity (VA).
  
  
  RESULTS
  The average pretreatment logarithm of the minimum angle of resolution (logMAR) VA was 0.65 (Snellen equivalent of 20/88). Mean follow-up was 22.43 weeks with an average of 1.8 intravitreal injections. Average final logMAR VA was 0.43 (Snellen equivalent of 20/54). Twenty eyes (71%) experienced an increase in central VA, whereas four eyes (14%) were unchanged and four eyes (14%) experienced a decrease in vision.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab may improve or stabilize VA in a significant majority of patients with neovascular complications of OHS (24 eyes [85.7%] in our study population).
authors.affiliation: Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Missouri, USA.
authors.forename: Ramin
authors.initials: R
authors.lastname: Schadlu
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Blinder
authors.forename: Gaurav K
authors.initials: GK
authors.lastname: Shah
authors.forename: Nancy M
authors.initials: NM
authors.lastname: Holekamp
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Thomas
authors.forename: M Gilbert
authors.initials: MG
authors.lastname: Grand
authors.forename: Nicholas E
authors.initials: NE
authors.lastname: Engelbrecht
authors.forename: Rajendra S
authors.initials: RS
authors.lastname: Apte
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Joseph
authors.forename: Anita G
authors.initials: AG
authors.lastname: Prasad
authors.forename: Bradley T
authors.initials: BT
authors.lastname: Smith
authors.forename: Arsham
authors.initials: A
authors.lastname: Sheybani
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D015821:Eye Infections, Fungal / Q000150:complications*; D005260:Female; D005500:Follow-Up Studies; D006658:Histoplasma / Q000302:isolation & purification; D006660:Histoplasmosis / Q000150:complications*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab